Back to Newsroom

ProMIS Neurosciences Announces Successful Humanization of Lead Product Candidate PMN310 for Alzheimer’s Disease

TORONTO, Ontario and Cambridge, Massachusetts – September 19, 2017 – ProMIS Neurosciences, Inc., a company focused on discovery and development of precision treatments for neurodegenerative diseases, today announced the successful humanization of its lead product candidate for Alzheimer’s disease (AD), PMN310, a monoclonal antibody (mAb) targeting toxic prion-like forms of amyloid-beta oligomers (AβO).